CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:

Cantor Global Healthcare Conference – presenting Friday, September 5, 2025, at 10:20am ET in New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference – presenting Tuesday, September 9, 2025, at 7:45am ET in New York, NY

Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.

About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com

Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology megan.knight@cgoncology.com